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Abstract
Metastatic uveal melanoma (UM) patients usually die within one year of diagnosis, emphasizing 
an urgent need to develop new treatment strategies. The liver is the most common site of 
metastasis. Mitogen-activated protein kinase kinase (MEK) inhibitors improve survival in V600 
BRAF-mutated cutaneous melanoma patients but have limited efficacy in UM patients. Our 
previous work showed that HGF signaling elicits resistance to MEK inhibitors in metastatic UM. 
In this study, we demonstrate that expression of two BH3-only family proteins, Bim-EL and BMF, 
contributes to HGF-mediated resistance to MEK inhibitors. Targeting HGF-cMET signaling with 
LY2875358, a neutralizing and internalizing anti-cMET bivalent antibody, and LY2801653, a dual 
cMET/RON inhibitor, overcomes resistance to trametinib provided by exogenous HGF and by 
conditioned medium from primary hepatic stellate cells. We further determined that activation of 
PI3Kα/γ/δ isoforms mediates the resistance to MEK inhibitors by HGF. Combination of 
LY2801653 with trametinib decreases AKT phosphorylation and promotes pro-apoptotic PARP 
cleavage in metastatic UM explants. Together, our data support the notion that selectively blocking 
cMET signaling or PI3K isoforms in metastatic UM may break the intrinsic resistance to MEK 
inhibitors provided by factors from stromal cells in liver.
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Introduction
Uveal melanoma (UM) is the most common intraocular malignant tumor in adults and 
comprises approximately 5% of all melanomas (1). Even after treatment of the primary 
tumor, 20–50% of patients succumb to metastatic disease. The liver is the predominant organ 
of metastasis. Standard chemotherapies and immune checkpoint blockers rarely induce 
clinical responses in patients with macro-metastasis and their 1-year survival is <30% (2). 
This knowledge emphasizes an urgent unmet need for effective therapeutic strategies for 
advanced UM.
Activating mutations in GNAQ and GNA11 (typically Q209 and less commonly R183), 
which encode alpha subunits of the heterotrimeric G proteins, Gαq and Gα11, are found in 
80–90% of UM (3–6). Silencing GNAQ induces apoptosis in mutant but not wild-type UM 
cells (4, 7). Mutant Gαq and Gα11 activate phospholipase C-β (PLC-β), which regulates 
several pathways including MEK-ERK1/2 and protein kinase C (PKC) signaling (8). In 
addition, PLC-β-independent activation of Trio, a guanine nucleotide exchange factor, 
transduces signaling downstream from Gαq to activate Yes-Associated Protein 1 (YAP) and 
promote UM tumorigenesis (9–11). In UM, GNAQ and GNA11 mutations occur early in 
disease progression; however, additional alterations are required (5, 12). Mutations in the 
tumor-suppressor BRCA1-associated protein 1 (BAP1) on chromosome 3 are found in 32–
50% of primary melanomas (13). BAP1 mutations associate with aggressive disease and 
higher likelihood of metastasis. Silencing BAP1 in primary UM cell lines results in a gain of 
stem-like properties with little/no effect on proliferation and invasion (14). Additional genes 
mutated in UM are SF3B1 and EIF1AX, which associate with a favorable prognosis (15–
17), PLCB4 (18) and CYSLTR2 (19).
A major effector pathway downstream of mutant Gαq and Gα11 is RAF-MEK1/2-ERK1/2 
signaling. Inhibition of MEK1/2 with trametinib or selumetinib induces either cell cycle 
arrest or apoptosis in UM cell lines (7, 20); however, clinical studies in advanced stage UM 
patients indicate that MEK inhibitors have limited clinical benefit. Trametinib was 
ineffective in a phase I trial cohort of 16 metastatic UM patients (21). A phase II trial with 
selumetinib in 120 patients showed a 9-week improvement in progression-free survival 
compared with standard chemotherapy, but no improvement in overall survival (22). In the 
most recent phase III trial with 129 patients (23), a combination of selumetinib and standard 
chemotherapy dacarbazine failed to improve progression-free survival compared with 
chemotherapy alone. Thus, while MEK inhibitor may form part of a therapeutic approach 
for advanced-stage UM, further investigation is required to identify inhibitors to act in 
combination.
The majority of UM patients with overt metastasis show primary resistance to MEK 
inhibitors, which may be mediated by factors from the tumor microenvironment. In UM cell 
monocultures, hepatocyte growth factor (HGF) provides resistance to MEK inhibitors (20). 
HGF is secreted by quiescent hepatic stellate cells. Consistent with the presence of HGF in 
tumor microenvironment, the majority of UM liver metastases express phosphorylated/
activated cMET (20). Together, these results suggest that MEK inhibitors in combination 
with cMET targeting agents may have utility in advanced UM. In this study, we explored the 
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molecular mechanism of HGF-mediated resistance to MEK inhibitors in UM cells and pre-
clinically evaluated the efficacy of co-targeting cMET with MEK inhibitor in metastatic cell 
lines and ex vivo explants. Our data show that down-regulation in the BH3-only proteins, 
Bim-EL and Bmf, contribute to HGF-mediated protective effect in metastatic UM cells. 
Clinical grade cMET targeting agents effectively overcome the resistance provided by 
exogenous HGF as well as factors derived from hepatic stellate cells. Combined inhibition 
of cMET and MEK1/2 enhances apoptotic signal in cell lines and an ex vivo explant model 
of metastatic UM. Together, these data provide a pre-clinical basis for combinational 
therapies targeting mutant Gαq/11 signaling and signaling initiated by factors from tumor 
microenvironment in advanced-stage UM patients.
Materials and Methods
Cell culture
UM001 and UM004 cells were derived from liver and orbital metastases of human UM, 
respectively; both harbor GNAQ Q209L mutations (20, 24). UM001 cells were cultured in 
RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 10% non-essential 
amino acids, 2 mM L-glutamine and 10 mM Hepes buffer. UM004 cells were maintained in 
MEM medium containing 10% heat-inactivated FBS and 2 mM L-glutamine. LX-2 human 
hepatic stellate cell line was purchased from EMD Millipore (Billerica, MA) and cultured in 
DMEM medium containing 2% FBS and 2 mM L-glutamine according to manufacturer’s 
protocol. Human hepatic stellate cells (HHSteC) were cultured in basal medium, 2% FBS 
and 1% stellate cell growth supplement according to manufacturer’s protocol (ScienCell 
Research Laboratories. Carlsbad, CA). HHSteC conditioned medium is collected from 
HHSteC cultures immediately before sub-culture. Medium conditioned by early passage (<6 
passages) HHSteC cultures was used for functional co-culture experiments with UM001 and 
UM004 cells.
Cell line validation
UM001 and UM004 cells were confirmed as harboring GNAQ mutations as determined by 
Sanger DNA sequencing. UM001 and UM004 cells were analyzed by STR analysis on 
January 15th, 2015; The UM001 and UM004 profiles were unique, although the latter had a 
94% match with 3 changed alleles to MDA-MB-330 cells on the DSMZ resource.
Inhibitors, growth factors and function-blocking antibodies
Trametinib (GSK1120212), MK2206 (PubChem compound database (CID, 24964624)), 
GDC0032 (25), TGX221 (26), BYL710 (25) and IPI145 (25) were purchased from Selleck 
Chemicals (Houston, TX). Recombinant human HGF was purchased from PeproTech 
(Rocky Hill, NJ) and used at 10 ng/ml based on our previous studies (20). The neutralizing 
and internalizing anti-cMET antibody, LY2875358, and the cMET/RON inhibitor, 
LY2801653 (27), were provided by Eli Lilly and Company (Indianapolis, IN).
Short-interfering RNA (siRNA) and transfection
UM004 cells (3 × 105) were seeded in 6-well plates overnight before transfection with 
chemically synthesized siRNAs at a final concentration of 25 nM using Lipofectamine™ 
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RNAiMAX (Invitrogen, Carlsbad, CA) as previously described (28). Bim-EL specific 
siRNAs (GACCGAGAAGGUAGACAAUUGTT and 
CAAUUGUCUACCUUCUCGGUCTT) were purchased from Cell Signaling Technology 
(Danvers, MA). Bmf specific siRNA (GAGUAACAGAUAACGAUUA) was purchased from 
Dharmacon Inc. (Lafayette, CO). A non-targeting siRNA 
(UAGCGACUAAACACAUCAAUU) was used as a control.
Western blotting
Cells were washed in cold PBS and lysed directly in Laemmli sample buffer. Lysates were 
resolved by SDS polyacrylamide gel electrophoresis and transferred to polyvinylidene 
difluoride membranes. Membranes were blocked with 1% BSA and incubated with 
indicated primary antibodies overnight at 4°C. Proteins were detected using the horseradish 
peroxidase-conjugated secondary antibodies followed by development using 
chemiluminescence substrate (Pierce, Rockford, IL). The following primary antibodies were 
used: ERK2 (D-2), Cyclin A and Noxa from Santa Cruz Biotech. Inc. (Santa Cruz, CA); 
Bcl-2, Bcl-xl, Mcl-1, Bax, Bad, Bid, Puma, cleaved caspase 3, cleaved PARP, RB, phospho-
RB (S780), cMET, phospho-cMET Y1234/1235 (D26), phospho-cMET Y1349, AKT, 
phospho-AKT T308 (C31E5E), phospho-AKT S473 (D9E), phospho-ERK1/2 (D13.14.4E), 
Stat3, phospho-Stat3 Y705, p110α-PI3K, p110β-PI3K and p110δ-PI3K from Cell Signaling 
Tech; cyclin D1 and Bcl-w from BD Pharmingen, p110δ-PI3K, α-SMA and FAP from 
Abcam (Cambridge, MA); Bim-EL and BMF from Enzo Life Sciences (Farmingdale, NY); 
Actin from Sigma-Aldrich (St Louis, MO) and Hsp90 (clone 4F3.E8) from StressMarq 
Biosciences (Victoria BC). Chemiluminescence was visualized on a ChemiDoc Imaging 
System and quantitated using Image Lab 4.1 software (Bio-Rad, Hercules, CA).
EdU incorporation assay
UM001 and UM004 cells were treated with DMSO, 50 nM trametinib, 10 ng/ml HGF or 
trametinib plus HGF for 32 hours before the addition of 10 µM EdU for another 16 hours. 
Cells were then processed using the Click-iT Plus EdU Alexa Fluor 647 Flow Cytometry 
Assay kit (Invitrogen) according to manufacturer’s protocol. Experiments were performed in 
triplicate and statistical analysis was performed using a two-tailed t test assuming unequal 
variance with error bars representing SD.
Annexin V/PI staining
Cells were trypsinized, washed with cold PBS and resuspended in 0.1 ml binding buffer. 
Cells were then stained with 5 µl of Annexin V-APC and 2 µl of propidium iodide (PI) for 
30 minutes at room temperature. Staining was then analyzed by flow cytometry on a BD 
FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ). Data were analyzed by 
FlowJo software (Tree Star, Inc., Ashland, OR). Experiments were performed in triplicate 
with statistical analysis as in EdU incorporation assay.
Crystal violet staining
Exponentially growing UM001 and UM004 cells were plated in 6-well or 12-well dishes 
and treated as described in figure legends. Cells were then stained with crystal violet 
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solution (1% crystal violet, 10% buffered formalin) for 30 minutes, washed and air dried. 
Plates were imaged by scanning while pictures were taken at ×100 magnification on the 
Nikon™ Eclipse Ti inverted microscope with NIS-Elements AR 3.00 software (Nikon, 
Tokyo, Japan). Crystal violet staining images were quantitated using Image J. Experiments 
were performed in triplicate and statistical analysis performed using a two-tailed t test 
assuming unequal variance
Enzyme-linked immunosorbent assay (ELISA)
HGF levels in conditioned medium collected from stellate cell cultures were measured with 
ELISA kits (Invitrogen), according to the manufacturer’s instructions.
Migration and invasion assays
Sub-confluent UM001 and UM004 cells were cultured overnight in serum-free medium. For 
migration assays, 1 × 104 cells in serum-free medium were placed inside 8.0 µm pore-size 
cell culture inserts (BD Biosciences, San Jose, CA). For invasion assays, the inserts were 
first coated with 0.75 mg/ml Matrigel (BD Biosciences) for one hour before plating cells 
inside each chamber. Cells were allowed to migrate or invade for 16 hours towards an 
attractant of stellate cell culture medium or conditioned medium from passage 3 stellate 
cells. Chamber filters were fixed in buffered formalin and stained with crystal violet. Cells in 
the inner chamber were removed. Images were taken with a Nikon™ Eclipse Ti inverted 
microscope at 100 × magnification.
Reverse phase protein array (RPPA) analysis
UM001 and UM004 cells were plated in 6-well dishes at 4 × 105 cells per well. Cells were 
treated with unconditioned medium or passage 2 HHSteC conditioned medium for either 1 
hour or 48 hours. Cells were lysed and prepared as previously described (29) and analyzed at 
the MD Anderson Functional Proteomic core facility (Houston, TX). Serial dilutions of 
samples were arrayed on nitrocellulose-coated slides and run against 295 validated 
antibodies. Spot density was determined using MiroVigene and analyses of triplicate 
normalized data were performed using SuperCurve. Hierarchical clustering of the 295 
antibodies was performed via the clustergram function in Matlab® (version 2015b) on RPPA 
median-centered log2 expression values. The samples were pre-sorted based on cell line, 
treatment type, time point and replicate number.
Ex vivo UM explants
Human metastatic UM tissue was collected following patient consent at Thomas Jefferson 
University Hospital under an IRB-approved protocol (#02.9014R). Less than 16 hours post-
surgery, excess adipose and stromal tissue was removed and the tumor (Explant of Patient 
No.4/Ex-Pt#4) was cut into 1 mm3 pieces. Vetspon absorbable hemostatic gelatin 1 cm3 
sponges (Novartis, Basel, Switzerland) were pre-soaked in 12-well plates for 15 minutes at 
37°C in 500 µL of DMEM medium containing 10% FBS, penicillin-streptomycin and drugs. 
DMSO was used as a vehicle control. To avoid concerns of intra-tumoral heterogeneity, up 
to four ~1 mm3 pieces from different locations of the original tumor were placed per sponge 
per treatment condition. Samples were treated for 48 hours with medium being replaced 
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after 24 hours. Tumor pieces for western blotting were homogenized in lysis buffer with 
phosphatase and protease inhibitors (PhosSTOP and cOmplete tablets, Roche, Basel, 
Switzerland). Laemmli sample buffer was added and samples were heated at 99°C for 5 
minutes.
Statistical Analysis
Statistical analyses were performed using SPSS v22.0 (IBM, Armonk, NY, USA). One-way 
ANOVA analyses were performed on normalized data from groups of equal sizes. No 
outliers were identified during inspection of boxplots. All of the groups were determined to 
be normally distributed using Shapiro–Wilk’s test (P > 0.05). There was homogeneity of 
variances among all groups, as determined by Levene’s test of equality of variances (P > 
0.05). Dunnett’s one-tailed multiple comparison post-hoc tests were performed to determine 
statistical significance.
Results
HGF promotes G1/S cell cycle progression and decreases cytotoxicity of trametinib-
treated cells
We determined whether HGF-mediated resistance to MEK inhibitors in UM cells was 
associated with effects on S-phase entry (EdU incorporation) and/or apoptosis (annexin V/PI 
staining). HGF was used at 10 ng/ml based on our previous studies (20). In UM001 and 
UM004 cells, trametinib treatment resulted in > 90% decrease in EdU incorporation (Fig 
1A) and 45–60% increase in annexin V staining (Fig 1B). Treatment with HGF in the 
absence of MEK inhibition elicited minimal effect on S-phase entry and apoptosis. By 
contrast in trametinib-treated UM001 and UM004 cells, HGF restored S-phase entry by 70% 
and 40% respectively compared with DMSO controls (Fig 1A). Additionally, HGF 
significantly reduced the annexin V population in trametinib-treated UM001 and UM004 
cells (Fig 1B; Suppl Fig 1).
We next analyzed the cell cycle profiles of UM001 and UM004 cells treated with HGF, 
trametinib or the combination of HGF plus trametinib. Trametinib treatment was associated 
with changes in G1/S regulators including lower expression of cyclin A2 and cyclin D1 and 
reduced retinoblastoma (RB) phosphorylation (Fig 1C). Down-regulation of total RB 
expression following trametinib treatment was also detected, an effect previously observed 
in breast cancer cell lines following inhibition of cell cycle progression with CDK4/6 
inhibitors (30, 31). MEK inhibition increased expression of the apoptotic markers, cleaved 
PARP and cleaved caspase 3. Notably, trametinib-treated cells treated with HGF showed a 
partial recovery of cyclin A2, cyclin D1 and phospho-RB levels. HGF also modestly 
increased levels of phosho-ERK1/2 in trametinib-treated cells. Additionally, the induction of 
cleaved PARP and cleaved caspase 3 was mitigated by HGF in trametinib-treated cells (Fig 
1C). Together, these data indicate that HGF promotes the growth of trametinib-treated cells 
through restoration of cell cycle progression and inhibition of apoptosis.
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Down-regulation of Bim-EL and Bmf contributes to HGF-mediated resistance to trametinib 
in UM cells
To molecularly understand how HGF counteracts trametinib-mediated apoptosis, we 
compared the levels of Bcl-2 family proteins in UM cells treated with HGF, trametinib, or 
the combination of both. We also treated cells with MK2206 to evaluate the role of AKT 
activity. HGF promoted the phosphorylation of AKT in the presence of trametinib, an effect 
that was diminished by MK2206 (Fig 2A). Trametinib treatment did not alter expression of 
anti-apoptotic proteins, Bcl-w, Bcl-xl, multi-domain pro-apoptotic proteins, Bak and Bax, or 
BH3-only proteins Bad, Bid and Noxa in UM001 and UM004 cells (Fig 2A). By contrast, 
the BH3-only pro-apoptotic proteins, Bcl-2-interacting mediator of cell death-extra large 
(Bim-EL) and Bcl-2 modifying factors (Bmf) were up-regulated in trametinib-treated cells. 
The induction of Bim-EL and Bmf was diminished or markedly reduced when HGF was 
supplemented to trametinib-treated UM cells (Fig 2A). Notably, Bim-EL and Bmf levels 
were re-induced in cells treated with a combination of trametinib, HGF and MK2206, 
suggesting that HGF activation of AKT mediates the resistance to trametinib. A modest up-
regulation of the pro-survival protein Bcl-2 and the BH3-only pro-apoptotic protein, Puma, 
was detected with trametinib treatment in one (Puma) or both (Bcl-2) cell lines (Fig 2A).
To determine whether up-regulation of Bim-EL and Bmf is required for trametinib-induced 
inhibition of cell viability, Bim-EL and/or Bmf-silenced UM004 cells were treated with 
trametinib (Fig 2B) and evaluated by crystal violet staining (Fig 2C). In comparison to 
controls, trametinib decreased cell viability by ~60% (Fig 2C). Individual knockdown of 
Bim-EL and Bmf each partially rescued cells from trametinib with cell viability inhibited by 
32–39%; however, simultaneous silencing of Bim-EL and Bmf further restored the viability 
of trametinib-treated cells with cell growth decreased by ~26% of the control (Fig 2C). To 
examine whether Bim-EL and Bmf are sufficient to promote UM cell apoptosis, UM001 and 
UM004 cells were infected with adenoviruses to express Bim-EL, Bmf and enhanced green 
fluorescence protein (eGFP), as a control. Ectopic expression of Bim-EL and/or Bmf 
significantly increased apoptosis in UM cells, while expression of eGFP showed little effect 
(Suppl Fig 2). These results suggest that Bim-EL and Bmf are sufficient to induce apoptosis 
and are down-regulated in HGF-mediated resistance to MEK inhibitors.
LY2801653 and LY2875358 abrogates HGF-mediated resistance to trametinib in UM cells
To inhibit HGF-mediated signaling, we utilized two cMET targeting agents that are being 
tested in clinical trials for UM patients with liver metastasis as well as other advanced 
cancers. Of these two agents, LY2801653 is a type II kinase inhibitor with cMET as one of 
its target and displays anti-tumor activity in non-small cell lung carcinoma and 
cholangiocarcinoma preclinical models (32–34). LY2875358 is a neutralizing and 
internalizing anti-cMET bivalent antibody that showed potent anti-tumor activity in both 
HGF-dependent and cMET amplified preclinical tumor models (35). Initially, UM001 and 
UM004 cells were treated with increasing doses of LY2801653 and LY2875358 followed by 
HGF stimulation. Both cMET inhibitors effectively blocked HGF-induced phosphorylation 
of ERK1/2, AKT and cMET at tyrosine 1349 (Fig 3A and 3B). Phosphorylation at tyrosine 
1349 in the cMET cytoplasmic domain provides a direct binding site for Gab1 (36), which 
promotes AKT pathway activation. Of note, LY2875358 had minimal effect on HGF-
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induced phosphorylation of cMET at tyrosine 1234/5 (Fig 3A and 3B), critical sites for 
kinase activation. We evaluated the ability of these two cMET targeting agents in 
overcoming HGF-mediated resistance to trametinib in UM cells. LY2801653 alone did not 
significantly alter UM001 and UM004 cell growth at 100 nM; however, growth of 
trametinib-treated UM cells which decreased by ~57% compared to the vehicle control was 
further inhibited when treated with LY2801653 (Fig 3B). The viability of trametinib/
LY2801653 co-treated UM001 and UM004 cells decreased by 81% and 64%, respectively, 
of the vehicle control. Importantly, HGF-mediated growth protection from trametinib 
treatment was abrogated by LY2801653 (Fig 3B). Similarly, LY2875358 alone had little 
effects on UM001 and UM004 cell growth. Although LY2875358 did not further inhibit 
growth of trametinib-treated cells, LY2875358 blocked HGF-mediated protection from 
trametinib (Fig 3C). The viability of trametinib-treated UM001 and UM004 cells was 
increased to levels similar to the vehicle control when cells were treated with HGF; an effect 
that was decreased with LY2875358 by 44% in UM001 and 25% in UM004 compared to 
vehicle control (Fig 3C). Together, these data demonstrate that targeting HGF signaling with 
clinical grade cMET neutralizing antibody and inhibitor overcomes HGF-mediated 
resistance to trametinib in metastatic UM cells.
Primary hepatic stellate cell medium protects UM cells against trametinib through HGF-
cMET signaling
Basal phosphorylation of cMET and downstream signaling is low in UM lines and 
understanding the communication between cancer cells and the stroma in the metastatic site 
is necessary for the development of optimal therapeutic regimens. UM frequently 
metastasizes to the liver. Hepatic stellate cells are intralobular connective tissue cells that are 
quiescent in a healthy liver, but transition into myofibroblast-like cells and become activated 
during liver fibrosis and hepatocellular carcinomas (37). Current available stellate cell lines 
are either immortalized by hTERT or become activated due to long time culture and 
therefore at least partially lose characteristics of their primary origins (38). Therefore we 
utilized primary stellate cells that were isolated from human liver. These cells were cultured 
for up to six passages to minimize their activation, passages at which they did not express 
the fibroblast markers, α-SMA and FAP (Suppl Fig 3A).
To better understand the effects of hepatic stellate cells on UM cells, we first performed 
high-throughput antibody-based RPPA analysis on UM001 and UM004 cells incubated for 1 
hour or 48 hours with either unconditioned medium or stellate cell conditioned medium. 
Supervised clustering of proteins that were regulated by stellate cell conditioned medium 
and further significance analysis of microarrays (SAM) identified several proteins that were 
differentially regulated by addition of stellate cell conditioned medium (Fig 4A; Suppl Fig 
3B). In both UM001 and UM004 cells, PI3K/AKT and ERK/MAPK signaling were the most 
activated pathways by stellate cell medium (Fig 4A). We performed Western blot analysis to 
validate the RPPA findings. In UM001 and UM004 cells, conditioned medium from stellate 
cells rapidly induced phosphorylation of ERK1/2, AKT, cMET, and Stat3 (Fig 4B). We also 
demonstrated that HGF was present at ng/ml levels in the conditioned medium from early 
passages of primary hepatic stellate cells by ELISA (Suppl Fig 3C). In contrast, the 
conditioned medium from an immortalized human hepatic stellate cell line did not induce 
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cMET activation (Suppl Fig 3D). Consistent with the known role of HGF (39), we showed 
that stellate cell conditioned medium promoted the migration and invasion of UM001 and 
UM004 cells (Suppl Fig 4).
To determine whether conditioned medium from stellate cells drives resistance to trametinib 
though HGF-cMET pathway activation, we cultured UM001 and UM004 cells in either 
unconditioned medium or stellate cell conditioned medium. Factors from stellate cells 
protected UM cells from trametinib-induced growth inhibition as the viability of UM cells 
cultured in conditioned medium increased by 2–3 fold compared to trametinib treatment/non 
conditioned medium conditions (Fig 4C). Importantly, stellate cell conditioned medium 
protection to trametinib was restored by LY2875358 and LY2801653, with LY2801653 
being more potent in sensitizing UM cells (85–90% reduction in cell viability compared to 
the vehicle control). This suggests that LY2801653 is a more effective cMET inhibitor 
and/or signaling molecules other than cMET may play a role in response to trametinib in 
UM cells (Fig 4C). However, together these data indicate that factors from hepatic stellate 
cells elicit innate resistance to trametinib at least partially through HGF-cMET signaling.
HGF-mediated growth protection from MEK inhibitors is reversed by PI3Kβ-sparing 
inhibitors
Since PI3K-AKT is a major pathway activated by HGF, we examined the dependency of 
PI3K isoforms on HGF-mediated AKT phosphorylation and HGF-mediated resistance to 
trametinib in UM cells. We utilized PI3K isoform specific inhibitors: GDC0032 is a PI3Kβ-
sparing isoform inhibitor targeting PI3Kα/δ/γ; TGX221 is a p110β-specific inhibitor; 
BYL719 is a selective PI3Kα inhibitor; and IPI145 is a selective PI3K δ/γ inhibitor. We first 
pre-treated UM001 (Suppl Fig 5) and UM004 cells (Fig 5) with increasing doses of 
individual inhibitors followed by HGF stimulation. All these four p110 isoforms were 
expressed in both UM001 and UM004 cells and expression was unchanged by HGF/
inhibitor treatments (Fig 5A, Suppl Fig 5A). The PI3Kβ-sparing isoform inhibitor GDC0032 
effectively blocked HGF-mediated AKT phosphorylation at 250 nM in UM001 cells and 50 
nM in UM004 cells. PI3Kα inhibitor BYL719 and PI3K δ/γ inhibitor IPI145 significantly 
inhibited HGF-mediated AKT phosphorylation at 500 nM, whereas the PI3Kβ specific 
inhibitor TGX221 did not block AKT phosphorylation even at 2.5 µM (Fig 5A, Suppl. Fig 
5A). We evaluated the ability of PI3K isoform specific inhibitors to overcome HGF-
mediated resistance to trametinib in these cells. Individual inhibitors at 500 nM elicited no 
effect or minimal effect on cell growth (Fig 5B, Suppl Fig 5B). HGF-mediated growth 
protection in trametinib-treated UM001 cells (Suppl Fig 5B) and UM004 cells (Fig 5B) was 
reverted by GDC0032 (37% reduction in UM004 cell growth compared to vehicle control) 
and partially reverted by BYL719 and IPI145 (12–17% inhibition of UM004 cell growth 
compared to vehicle control). Additionally, PI3Kβ-specific inhibitor TGX221 failed to 
markedly induce growth inhibition in HGF and trametinib treated cells. These data suggest 
PI3Kα/δ/γ, but not PI3Kβ, account for HGF-mediated AKT phosphorylation and resistance 
to MEK inhibition in UM cells.
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LY2875358 combines with MEK1/2 targeting to promote apoptotic index in metastatic UM 
explants
To test whether combined therapies targeting MEK1/2 and HGF-cMET signaling improves 
the response in metastatic UM, We next extended our study to analyze a mutant GNAQ 
harboring UM patient sample using an ex vivo treatment approach (Fig 6A Supplementary 
Table S1). Tumor tissue pieces were treated with DMSO, trametinib, LY2875358, or a 
combination of trametinib and LY2875358. As expected, treatment with trametinib inhibited 
the phosphorylation of ERK1/2 (Fig 6B), suggesting that ex vivo treatment of patient-
derived explants is a feasible strategy for testing drug response in UM. Ex vivo treatment 
with trametinib also promoted apoptosis, as evidenced by an increased expression of 
cleaved-PARP. Interestingly, combination of trametinib with LY2875358 further upregulated 
the expression of cleaved-PARP. These data are supportive that a combined therapy with 
MEK and cMET inhibition may represent a novel and effective strategy in treating 
metastatic UM patients.
Discussion
The majority of UM metastases show a tropism for the liver and are highly resistance to 
targeted therapies such as MEK inhibitors. How the tumor microenvironment regulates the 
response in UM to targeted inhibitors is poorly understood. Here we utilized cell lines 
derived from metastatic UM and conditioned medium derived from stromal cells in the liver 
microenvironment. We provide evidence that the use of cMET targeting agents as a part of 
combinational approach may counteract tumor microenvironment-mediated primary 
resistance to MEK inhibitors in mutant GNAQ/11 metastatic UM.
Recent results from the phase III, randomized trial (NCT01974752) of the MEK inhibitor, 
selumetinib, in combination with dacarbazine in patients with metastatic UM were 
disappointing with only 3 out 97 patients treated with the combination eliciting a partial 
response based on a central review. These results are in contrast to findings in cutaneous 
melanoma, which led to the FDA approval of trametinib for the treatment of BRAF 
V600E/K unresectable or metastatic cutaneous melanoma (40). HGF is abundant in the liver 
microenvironment and, when supplied exogenously, rescues the growth of MEK-inhibited 
mutant GNAQ human metastatic UM cell lines (20). Our data herein indicate that HGF-
mediated resistance to MEK inhibitors in UM cells involves silencing of the pro-apoptotic, 
Bim-EL and Bmf. These data are similar to the role of Bim-EL and Bmf in resistance to the 
BRAF inhibitor, PLX4720, in cutaneous melanoma cells (41).
To investigate the effect of liver microenvironment on response to MEK inhibitors in UM 
cells, we examined factors derived from human hepatic stellate cells. Early passage human 
stellate cells do not display activation markers and do secrete HGF indicating that they may 
be an appropriate model for studying stromal contributions from the metastatic UM tumor 
microenvironment. Pro-HGF is subsequently cleaved to form HGF, which acts as a growth 
factor for hepatocytes (42). cMET is expressed in both primary and metastatic UMs, but 
metastatic lesions tend to have higher cMET expression levels (43), which is activated in the 
majority of UM liver metastases (20). Indeed, cMET signaling is constitutively activated in 
UM cells when cultured in conditioned medium from stellate cells. These data support a role 
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for tumor microenvironment in regulating HGF-cMET signaling in metastatic UM, which is 
mediated by stellate cell - cancer cell communication in the liver.
While UM cells are sensitive to trametinib in regular growth medium, they are resistant 
when grown in conditioned medium derived from stellate cells. Importantly, resistance is 
overcome by cMET targeting agents. These data suggest that innate/intrinsic resistance of 
UM to MEK inhibitors is driven, at least in part, by HGF from stellate cells in the liver 
microenvironment. We demonstrate that cMET targeting agents such as LY2801653 and 
LY2875358 may improve the response to MEK inhibitors in metastatic UM patients. We 
extended our studies to analyze a UM surgical specimen in an ex vivo treatment approach, 
which maintains the tumor microenvironment. Interestingly, we observed that LY2801653 
treatment promoted the expression of cleaved PARP, an indicator of apoptosis. We 
acknowledge that further studies using preclinical models are important to address the effect 
of combinational MEK1/2 and cMET based target therapy in metastatic UM.
The main activated downstream pathway of HGF-cMET is PI3K-AKT signaling. In the 
presence of trametinib, HGF promotes the activation of PI3K/AKT, which compensates for 
loss of MEK-ERK1/2 activity in UM cells (20). Despite the evidence highlighting the 
importance of the PI3K pathway activation in the development of resistance to target therapy 
in melanoma, initial testing of class I PI3K inhibitors in patients has not produced dramatic 
results mainly due to the overlapping toxicities with MEK inhibitors that limits their 
effective dosing (44). One possible way to overcome this limitation is to utilize PI3K 
isoform specific inhibitors. We identified that PI3Kα/γ/δ isoforms, but not PI3Kβ, are 
responsible for HGF-mediated AKT activation and HGF-mediated resistance to MEK 
inhibitors. These data suggest that the use of PI3Kβ-sparing inhibitors may represent a 
useful strategy to overcome HGF-mediated resistance and subsequently improve responses 
to MEK inhibitors in metastatic UM. Of note, in cutaneous BRAF-mutated GEM melanoma 
models, the combination of MEK inhibitor plus the PI3Kβ-sparing inhibitor enhanced initial 
tumor regression and forestalled the onset of tumor resistance (45).
In summary, the data presented here show for the first time that stellate cells from the liver 
provide innate resistance to MEK inhibitors in metastatic UM though HGF-cMET signaling. 
We have provided evidence that down-regulation of the BH3-only proteins, Bim-EL and 
Bmf, contributes to HGF-mediated resistance. Blocking HGF signaling with either clinical-
grade cMET targeting agents or PI3Kα/γ/δ inhibitors in UM cells overcome resistance to 
MEK inhibitors mediated by stellate cells or exogenous HGF. Ongoing efforts include 
testing anti-cMET monoclonal antibodies in combination with MEK inhibitors in preclinical 
UM studies. In addition, profiling other factors within hepatic cellular architecture that 
regulate response to targeted therapy may identify novel targets for more effective 
therapeutic strategies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. HGF promotes cell cycle progression of trametinib-treated UM cells
(A) HGF promotes S-phase entry in trametinib-treated cells. 3.0 × 105 UM001 cells and 
UM004 cells were seeded in triplicates and treated with DMSO, 50 nM trametinib, 10 ng/ml 
HGF, and a combination of 50 nM trametinib and HGF, respectively, for a total of 32 hours. 
A final concentration of 10 µM EdU was allowed to incorporate for 16 hours before 
processing. S-phase entry is normalized to DMSO condition, and data points are indicative 
of 3 experimental repeats. *P<0.05, **P<0.01, ***P<0.001. (B) HGF inhibits trametinib-
induced apoptosis in UM cells. UM001 and UM004 cells were treated with DMSO, 10 
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ng/ml HGF, 50 nM trametinib, a combination of HGF and trametinib, respectively, for 48 
hours. Cells were then subjected to annexin V/PI staining. The percentage of annexin V-
positive cells is graphed. *P<0.05, **P<0.01, ***P<0.001. (C) HGF modulates expression 
of cell cycle regulators in trametinib-treated cells. UM001 cells (left) and UM004 cells 
(right) were treated with 50 nM trametinib, 10 ng/ml HGF, 2.5 µM MK2206, or 
combinations as indicated for 48 hours. Cell lysates were probed for levels of cell cycle 
regulators cyclin A2, cyclin D1, phospho-RB, RB, cleaved PARP and cleaved caspase 3, 
respectively. Levels of pAKT and pERK were also determined by Western blotting.
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Figure 2. Downregulation of Bim-EL and BMF contributes to HGF-mediated resistance to 
trametinib in UM cells
(A) HGF inhibits trametinib-induced Bim-EL and Bmf expression in UM cells. UM001 cells 
(left) and UM004 cells (right) were treated with 50 nM trametinib, 10 ng/ml HGF, 2.5 µM 
MK2206, or combinations as indicated for 48 hours. Cell lysates were analyzed for 
expression of indicated BH3-only pro-apoptotic proteins (Bim-EL, Bmf, Bad, Bid, Noxa and 
Puma), multi-domain pro-apoptotic proteins (Bax and Bak) and anti-apoptotic proteins 
(Bcl-2, Bcl-w, Bcl-xl and Mcl-1). Actin was used as loading control. (B) Silencing of Bim-
EL and Bmf in UM cells. UM004 cells were transfected with 20 nM control siRNA, Bim-
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EL siRNA, Bmf siRNA or Bim-EL/Bmf siRNA. Expression of Bim-EL and Bmf was 
examined by Western blotting with indicated antibodies. (C) Silencing of Bim-EL and Bmf 
renders UM cells resistant to trametinib-induced apoptosis. UM cells were transfected with 
siRNAs, as above. 48 hours post-transfection, cells were treated with DMSO or 50 nM 
trametinib for another 48 hours. Cell growth was determined by crystal violet staining. 
Representative images of the cells at 100× magnification are shown. The scale bar is equal to 
100 µm. Quantitation of crystal violet staining is presented as mean of percentage crystal 
violet from triplicate experiments following normalization to siCtl. *P<0.05, **P<0.01, 
***P<0.001.
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Figure 3. Clinical grade cMET targeting agents, LY2801653 and LY2875358, overcome HGF-
mediated resistance to trametinib in UM cells
(A) A dual cMET/RON small-molecule inhibitor LY2801653 and a bivalent cMET 
monoclonal antibody LY2875358 block HGF/cMET signaling. UM001 cells and UM004 
cells were pretreated with increasing doses of LY2801653 (left) and LY2875358 (right) 
overnight. The next day cells were stimulated with 10 ng/ml HGF for 30 minutes. 
Phosphorylation of cMET, AKT and ERK1/2 was assessed by Western blotting. (B) HGF-
induced resistance to trametinib is reversed by LY2801653. UM001 cells (top) and UM004 
cells (bottom) were treated with DMSO or 50 nM trametinib, in combination with 10 ng/ml 
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HGF and/or 100 nM of LY2801643 as indicated for 48 hours (UM004) or 72 hours 
(UM001). Cells were washed and stained with crystal violet. Images were taken (100 × 
magnification). Scale bar is equal to 100 µm. The mean of percentage crystal violet from 
triplicate experiments following normalization to vehicle control is shown. *P<0.05, 
**P<0.01, ***P<0.001.
(C) HGF-induced resistance to trametinib is reversed by LY2875358. UM001 cells (top) and 
UM004 cells (bottom) were first treated with 10 µg/ml LY2875358 for 45 min, followed by 
10 ng/ml HGF and 50 nM trametinib for 48 hours (UM004) or 72 hours (UM001). Cells 
were stained with crystal violet. Representative microscopic images are shown (100 × 
magnification). Scale bar is equal to 100 µm. The percentage of crystal violet is normalized 
to vehicle control and the mean of percentage crystal violet from triplicate experiments is 
shown. *P<0.05, **P<0.01, ***P<0.001.
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Figure 4. Human hepatic stellate cells promote resistance to trametinib through HGF-cMET 
signaling in UM cells
(A) UM001 and UM004 cells were incubated with unconditioned medium or passage 2 
human hepatic stellate cells (HHSteC) conditioned medium for 1 hour or a total of 48 hours. 
Cell lysates were subjected to RPPA analysis against 295 validated antibodies. Significance 
analysis of microarray for RPPA of UM001 cells (left) and UM004 cells (right) growing in 
unconditioned medium or stellate cells conditioned medium was shown. (B) Stellate cells 
conditioned medium stimulates cMET signaling cascades. UM001 and UM004 cells were 
incubated with unconditioned medium and stellate cells conditioned (passage 2, 5 and 6) for 
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one hour. Levels of pcMET, pStat3, pAKT and pERK1/2 were assessed by Western blotting. 
(C) HHSteC conditioned medium renders resistance to trametinib through cMET in UM 
cells. UM001 cells (left) and UM004 cells (right) were cultured in unconditioned medium or 
passage 5 (p5) HHSteC conditioned medium and treated with 50 nM trametinib, with or 
without 25 ng/ml LY2875358 and 100 nM LY2801653 for 48 hours (UM004) or 72 hours 
(UM001). Cell growth was determined by crystal violet staining. Representative microscopic 
images are shown (100 × magnification). Scale bar is equal to 100 µm. The percentage of 
crystal violet is normalized to non-CM control and the mean of percentage crystal violet 
from triplicate experiments is shown. *P<0.05, **P<0.01, ***P<0.001.
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Figure 5. HGF-mediated resistance to trametinib is dependent on PI3Kβ-sparing isoforms in UM 
cells
(A) Isoform specific PI3K inhibitors differentially block HGF-mediated activation of AKT 
in UM cells. UM004 cells were pretreated with increasing doses of GDC0032, TGX221, 
BYL719 and IPI145 for 6 hours. Cells were then stimulated with 10 ng/ml HGF for 30 
minutes. Cell lysates were probed with pAKT, AKT, PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and 
actin antibodies. (B) PI3Kβ-sparing inhibitor GDC0032, but not PI3Kβ inhibitor TGX221, 
abrogates HGF-mediated resistance to trametinib in UM cells. UM004 cells were treated 50 
nM trametinib, 10 ng/ml HGF, 0.5 µM of GDC0032, TGX221, BYL719 or IPI145 
Cheng et al. Page 23
Mol Cancer Ther. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
respectively or in combination for 48 hours. Cells were stained with crystal violet. 
Representative microscopic images are shown (100× magnification). Scale bar is equal to 
100 µm. The percentage of crystal violet is normalized to vehicle control and the mean of 
percentage crystal violet from triplicate experiments is shown. *P<0.05, **P<0.01, 
***P<0.001, ns: not significant.
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Figure 6. Trametinib and LY2875358 combine to inhibit AKT activation and promote apoptosis 
in UM explants
(A) Schematic diagram of ex vivo treatment of UM explants. Fresh UM tumors obtained 
from surgery were cut into approximately 1 mm3 pieces and plated on Vetspon absorbable 
hemostatic gelatin sponges for 48 hours. The sponges were pre-soaked in medium 
containing DMSO, 50 nM trametinib, 100 nM LY2801653 or a combination of trametinib 
and LY2801653, respectively. Medium was replenished every 24 hours. (B) Metastatic UM 
specimen Ex-Pt#4 was treated, as above. Tumor samples were lysed in RPPA lysis buffer 
after 48 hours of treatment. Lysates were probed with pERK1/2, ERK2, pAKT, AKT, 
cleaved-PARP and Hsp90 antibodies.
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